Diagnosis and management of moderate-to-severe irritable bowel syndrome with constipation (IBS-C) in the UK: the IBIS-C study (Record no. 76575)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02791cam a2200169 4500 |
| 001 - CONTROL NUMBER | |
| control field | NMDX7787 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 120401t2015 xxu||||| |||| 00| 0 eng d |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Millar, A. |
| 240 ## - UNIFORM TITLE | |
| Uniform title | <a href="Gut">Gut</a> |
| 245 ## - TITLE STATEMENT | |
| Title | Diagnosis and management of moderate-to-severe irritable bowel syndrome with constipation (IBS-C) in the UK: the IBIS-C study |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Date of publication, distribution, etc. | 2015 |
| 500 ## - GENERAL NOTE | |
| General note | NMUH Staff Publications |
| 500 ## - GENERAL NOTE | |
| General note | EMBASE |
| 500 ## - GENERAL NOTE | |
| General note | 64 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | <span style="font-size: 10pt;">Introduction The IBIS-C study assessed the burden of IBS-C in 6 European countries (France, Germany, Italy, Spain, Sweden, and UK). Here we present the diagnosis and management results for the UK. Method Observational study in patients (pts) diagnosed with moderate-to-severe IBS-C in the last five years (Rome-III criteria) with a 12-month follow-up (6 months retrospective and 6 months prospective, in order to assess health resource utilisation [HRU] prior to and after an active phase of the disease). Moderate- to-severe IBS-C was defined as an IBS-Symptom Severity Score (IBS-SSS) &gt;=175. Results 104 pts were included (79% severe, mean age [+/-SD] 45.5 +/- 14.6 years old, 93% female). Mean time since diagnosis: 2.6 +/- 4.0 years; mean symptom duration: 15.3 +/- 14.9 yrs. Diagnostic procedures were highly variable; the most common were blood tests (72%), colonoscopy (69%), and abdominal ultrasound (55%). At inclusion the most prevalent symptoms were abdominal pain (92%) and bloating (91%). Main ongoing comorbidities were anxiety (50%), chronic pain (44%), headache (40%), insomnia (33%), or dyspepsia (31%). 52% of pts had an average of 3.6 +/- 2.7 diagnostic tests during follow-up, the most common were haematology (29%) and clinical chemistry (29%) blood tests, and colonoscopy (13%). 93% of pts took prescription drugs (90% took prescription drugs for their IBS-C). The most common medication groups were: laxatives (81%), prokinetics (32%), antispasmodics (20%), and analgesics (18%) alone or in combination. Overall, 63% of pts took OTC medication for their IBS-C; the most common were laxatives (37%), prebiotics/ probiotics (14%), and peppermint oil (14%). In addition, 36% of pts received complementary therapies. Overall, marginal improvement was noted in symptom severity (IBS-SSS total score) between baseline (373 +/- 83) and the 6-month visit (324 +/- 113). Conclusion Moderate-to-severe IBS-C symptoms often remain undiagnosed for many years and degree of control does not improve over time even though there is a high degree of prescription medication use. Consequently, moderate-to-severe IBS-C continues to be a burden despite the availability of therapeutic interventions.&nbsp;[Conference abstract]</span> |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://gut.bmj.com/content/64/Suppl_1/A323.1">http://gut.bmj.com/content/64/Suppl_1/A323.1</a> |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection code | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Staff publications for NMDX | Ferriman information and Library Service (North Middlesex) | Ferriman information and Library Service (North Middlesex) | Shelves | 07/06/2022 | 07/06/2022 | 07/06/2022 | Book |